|
|
Erica L. McCoy, Ritsuko Iwanaga, Paul Jedlicka, Nee-Shamo Abbey, Lewis A. Chodosh, Karen A. Heichman, Alana L. Welm, Heide L. Ford
J Clin Invest. 2009;
119(9):2663
doi:10.1172/JCI37691
Abstract |
Full text
| PDF
| Supplemental material

S
ix1 is a developmentally regulated homeoprotein with limited expression in most normal adult tissues and frequent misexpression in a variety of malignancies. Here we demonstrate, using a bitransgenic mouse model, that misexpression of human Six1 in adult mouse mammary gland epithelium induces tumors of multiple histological subtypes in a dose-dependent manner. The neoplastic lesions induced by Six1 had an in situ origin, showed diverse differentiation, and exhibited progression to aggressive malignant neoplasms, as is often observed in human carcinoma of the breast. Strikingly, the vast majority of Six1-induced tumors underwent an epithelial-mesenchymal transition (EMT) and expressed multiple targets of activated Wnt signaling, including cyclin D1. Interestingly, Six1 and cyclin D1 coexpression was found to frequently occur in human breast cancers and was strongly predictive of poor prognosis. We further show that Six1 promoted a stem/progenitor cell phenotype in the mouse mammary gland and in Six1-driven mammary tumors. Our data thus provide genetic evidence for a potent oncogenic role for Six1 in mammary epithelial neoplasia, including promotion of EMT and stem cell–like features.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(26)
| Title and authors |
Publication |
Year |
SIX1 promotes epithelial–mesenchymal transition in colorectal cancer through ZEB1 activation
H Ono, I Imoto, K Kozaki, H Tsuda, T Matsui, Y Kurasawa, T Muramatsu, K Sugihara, J Inazawa
|
Oncogene
|
2012 |
The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer
A L Smith, R Iwanaga, D J Drasin, D S Micalizzi, R L Vartuli, A-C Tan, H L Ford
|
Oncogene
|
2012 |
<![CDATA[Epithelial-mesenchymal transition and cancer stem cells in tumor metastasis]]> : Epithelial-mesenchymal transition and cancer stem cells in tumor metastasis
Fan YIN, Xia XU, Dong-bao ZHAO
|
Acad J sec Mil Med Univ
|
2012 |
Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer
Lubna Qamar, Erin Deitsch, Aaron N. Patrick, Miriam D. Post, Monique A. Spillman, Ritsuko Iwanaga, Andrew Thorburn, Heide L. Ford, Kian Behbakht
|
Gynecologic Oncology
|
2012 |
Twist2 contributes to breast cancer progression by promoting an epithelial–mesenchymal transition and cancer stem-like cell self-renewal
X Fang, Y Cai, J Liu, Z Wang, Q Wu, Z Zhang, C J Yang, L Yuan, G Ouyang
|
Oncogene
|
2011 |
Cancer Stem Cells: Repair Gone Awry?
Fatima Rangwala, Alessia Omenetti, Anna Mae Diehl
|
Journal of Oncology
|
2011 |
Cancer stem cell subsets and their relationships.
Hai-Guang Liu, Chong Chen, Han Yang, Yi-Fei Pan, Xiao-Hua Zhang
|
J Transl Med
|
2011 |
Cancer stem cells: problems for therapy?
Malcolm R Alison, Susan ML Lim, Linda J Nicholson
|
J. Pathol.
|
2011 |
Role of TGF-β signaling in EMT, cancer progression and metastasis
Katia Savary, Aristidis Moustakas
|
Drug Discovery Today: Disease Models
|
2011 |
TC-VGC: A Tumor Classification System using Variations in Genes’ Correlation
Eunji Shin, Youngmi Yoon, Jaegyoon Ahn, Sanghyun Park
|
Computer Methods and Programs in Biomedicine
|
2011 |
|